Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rVV-740CTA Immunotherapy in Breast Cancer
NCT03110445Phase 1Withdrawn
- Sponsor
- University Hospital Basel
- Start
- Mar 2020
- Primary completion
- Sep 2021
- Modality
- Oncolytic Viruses, Vaccines & Immunotherapeutics
01
Overview
Phase 1, open-label, single-arm trial of rVV-740CTA in breast carcinoma, sponsored by University Hospital Basel. Primary endpoints: Number of Adverse Events at 2 years and Number of Serious Adverse Events at 2 years. Planned start Mar 2020; status: withdrawn.
02
Drugs
rVV-740CTA
03
Conditions
breast carcinoma
Beyond the preview
Go deeper on NCT03110445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03110445.